-
Product Insights
NewLikelihood of Approval Analysis for Acute Heart Failure
Overview How likely is it that the drugs in Acute Heart Failure will get approved? Will the drugs transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LoA) and phase transition success rate (PTSR) of drugs using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Acute Heart Failure Overview Acute heart failure (AHF) is a critical...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Factor VIII Replacement For Hemophilia A in Hemophilia A (Factor VIII Deficiency)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Recombinant Factor VIII Replacement For Hemophilia A in Hemophilia A (Factor VIII Deficiency) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Recombinant Factor VIII...
-
Product Insights
AHF – Worcester Memorial Auditorium Renovation – Massachusetts
Equip yourself with the essential tools needed to make informed and profitable decisions with our AHF - Worcester Memorial Auditorium Renovation - Massachusetts report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Recombinant Factor VIII Replacement for Hemophilia A
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Recombinant Factor VIII Replacement for Hemophilia A Drug Details rhFactor VIII is under development...
-
Product Insights
Coagulation Factor VIII (Antihemophilic Factor or AHF or Procoagulant Component or F8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players
Coagulation Factor VIII (Antihemophilic Factor or AHF or Procoagulant Component or F8) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players report provides in depth analysis on Coagulation Factor VIII (Antihemophilic Factor or AHF or Procoagulant Component or F8) targeted pipeline therapeutics. The report provides comprehensive information complete with Analysis by Indications, Stage of Development, Mechanism of Action (MoA), Route of Administration (RoA) and Molecule Type. The report also covers the descriptive pharmacological...
-
Product Insights
Acute Heart Failure Global Clinical Trials Review, H2, 2016
GlobalData's clinical trial report, “Acute Heart Failure Global Clinical Trials Review, H2, 2016" provides an overview of Acute Heart Failure clinical trials scenario. This report provides top line data relating to the clinical trials on Acute Heart Failure. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report...
-
Sector Analysis
Heart Failure – Global Drug Forecast and Market Analysis to 2028
Heart failure( HF) is a clinical syndrome where the heart is unable to meet the demands of the body with a sufficient blood supply. This can be due to structural or functional cardiac abnormalities which can be caused by unexpected injury such as myocardial infarction, or an underlying pathogenesis such as hypertension (Krum and Abraham, 2009). The heart then begins to employ compensatory mechanisms that soon become maladaptive - Frank-Starling mechanism, neurohormonal activation and ventricular remodeling. All of which help...